JP2001514655A - アルツハイマー病予防へのr−nsaid’sの利用 - Google Patents

アルツハイマー病予防へのr−nsaid’sの利用

Info

Publication number
JP2001514655A
JP2001514655A JP53961998A JP53961998A JP2001514655A JP 2001514655 A JP2001514655 A JP 2001514655A JP 53961998 A JP53961998 A JP 53961998A JP 53961998 A JP53961998 A JP 53961998A JP 2001514655 A JP2001514655 A JP 2001514655A
Authority
JP
Japan
Prior art keywords
nsaid
composition
disease
alzheimer
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP53961998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514655A5 (cg-RX-API-DMAC7.html
Inventor
ジェイ. ウェクター,ウイリアム
ディー. マクラッケン,ジョン
Original Assignee
ローマ リンダ ユニバーシティ メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/814,490 external-priority patent/US6160018A/en
Application filed by ローマ リンダ ユニバーシティ メディカル センター filed Critical ローマ リンダ ユニバーシティ メディカル センター
Publication of JP2001514655A publication Critical patent/JP2001514655A/ja
Publication of JP2001514655A5 publication Critical patent/JP2001514655A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP53961998A 1997-03-10 1998-03-04 アルツハイマー病予防へのr−nsaid’sの利用 Pending JP2001514655A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/814,490 US6160018A (en) 1995-03-13 1997-03-10 Prophylactic composition and method for alzheimer's Disease
US08/814,490 1997-03-10
PCT/US1998/004176 WO1998040061A1 (en) 1997-03-10 1998-03-04 Use of r-nsaid's for the prevention of alzheimer's disease

Publications (2)

Publication Number Publication Date
JP2001514655A true JP2001514655A (ja) 2001-09-11
JP2001514655A5 JP2001514655A5 (cg-RX-API-DMAC7.html) 2005-01-13

Family

ID=25215202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53961998A Pending JP2001514655A (ja) 1997-03-10 1998-03-04 アルツハイマー病予防へのr−nsaid’sの利用

Country Status (9)

Country Link
EP (2) EP1642575B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001514655A (cg-RX-API-DMAC7.html)
AT (2) ATE311865T1 (cg-RX-API-DMAC7.html)
AU (1) AU6682298A (cg-RX-API-DMAC7.html)
CA (1) CA2283255C (cg-RX-API-DMAC7.html)
DE (2) DE69841267D1 (cg-RX-API-DMAC7.html)
DK (1) DK0966277T3 (cg-RX-API-DMAC7.html)
ES (1) ES2253810T3 (cg-RX-API-DMAC7.html)
WO (1) WO1998040061A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510603A (ja) * 2002-10-07 2006-03-30 アンコール ファーマスーティカルズ インコーポレイテッド R−非ステロイド性抗炎症薬エステル及びそれらの使用
JP2007262091A (ja) * 2003-07-11 2007-10-11 Myriad Genetics Inc アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
JP2009530306A (ja) * 2006-03-17 2009-08-27 アメリカ合衆国 脊髄性筋萎縮症の治療およびその他用途のための化合物
JP2010529101A (ja) * 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163986B1 (es) * 1999-07-13 2003-02-16 Menarini Lab Acidos-alfa-arilpropionicos y arilaceticos como inhibidores de la ciclooxigenasa-ii.
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040127471A1 (en) * 2002-09-17 2004-07-01 Barry Reisberg Methods of treating age associated memory impairment (AAMI), mild cognitive impairment (MCI), and dementias with cell cycle inhibitors
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
CN108191846B (zh) 2008-12-04 2021-08-20 于崇曦 高穿透性组合物及其应用
HK1207562A1 (en) 2012-01-18 2016-02-05 苏州泰飞尔医药有限公司 High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
WO2015006489A1 (en) 2013-07-11 2015-01-15 University Of North Texas Health Science Center At Fort Worth Blood-based screen for detecting neurological disease in primary care settings
EP3074525B1 (en) 2013-11-26 2024-06-26 University of North Texas Health Science Center at Fort Worth Personalized medicine approach for treating cognitive loss
JP7412003B2 (ja) 2018-01-18 2024-01-12 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワース アルツハイマー病に罹患している患者の特定の亜集団を治療するためのnsaid及びドネペジルについてのコンパニオン診断
EP4076424A1 (en) * 2019-12-20 2022-10-26 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
FR2687915B1 (fr) * 1992-02-28 1995-05-05 Rhone Poulenc Rorer Sa Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r).
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6255347B1 (en) * 1996-06-21 2001-07-03 Advanced Research And Technology Institute Methods and compositions comprising R-ibuprofen

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006510603A (ja) * 2002-10-07 2006-03-30 アンコール ファーマスーティカルズ インコーポレイテッド R−非ステロイド性抗炎症薬エステル及びそれらの使用
JP2007262091A (ja) * 2003-07-11 2007-10-11 Myriad Genetics Inc アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス, インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
JP2009530306A (ja) * 2006-03-17 2009-08-27 アメリカ合衆国 脊髄性筋萎縮症の治療およびその他用途のための化合物
JP2010529101A (ja) * 2007-06-04 2010-08-26 テックフィールズ インコーポレイテッド 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用

Also Published As

Publication number Publication date
WO1998040061A1 (en) 1998-09-17
EP1642575A1 (en) 2006-04-05
CA2283255C (en) 2007-01-02
EP0966277B1 (en) 2005-12-07
DE69832695D1 (de) 2006-01-12
EP1642575B1 (en) 2009-10-28
EP0966277A1 (en) 1999-12-29
CA2283255A1 (en) 1998-09-17
DE69841267D1 (de) 2009-12-10
DK0966277T3 (da) 2006-03-27
ATE446748T1 (de) 2009-11-15
ES2253810T3 (es) 2006-06-01
DE69832695T2 (de) 2006-09-14
AU6682298A (en) 1998-09-29
ATE311865T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
US6160018A (en) Prophylactic composition and method for alzheimer&#39;s Disease
US5981592A (en) Method and composition for treating cystic fibrosis
US5955504A (en) Colorectal chemoprotective composition and method of preventing colorectal cancer
EP2285374B1 (en) Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
US20040067914A1 (en) R-NSAID esters and their use
CA2283255C (en) Use of r-nsaid&#39;s for the prevention of alzheimer&#39;s disease
JP2021008523A (ja) 過度のフィブリン沈着及び/または血栓形成に関連する病理学的状態の治療または予防のための化合物及び組成物
EP1143958B1 (en) Pharmaceutical composition and use of rnsaid for treating inflammation
JPH07507057A (ja) 解熱鎮痛方法および光学的に純粋なr(‐)ケトプロフェンを含有する組成物
AU696620B2 (en) Antipyretic and analgesic methods and compositions containing optically pure R-ketorolac
RU2250103C2 (ru) ПРИМЕНЕНИЕ (R)-АРИЛПРОПИОНОВЫХ КИСЛОТ ДЛЯ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЛЮДЕЙ И ЖИВОТНЫХ, НА КОТОРЫЕ МОЖНО ОКАЗЫВАТЬ ТЕРАПЕВТИЧЕСКОЕ ВОЗДЕЙСТВИЕ ПУТЕМ ИНГИБИРОВАНИЯ АКТИВАЦИИ NF-κВ
CN119868356B (zh) Cbl抑制剂nx1607在制备治疗动脉粥样硬化药物中的应用
US12042493B2 (en) Pharmaceutical compounds for use in treating Huntington&#39;s disease
TWI684465B (zh) 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
JP2002514208A (ja) 痴呆の治療及び予防におけるシクロオキシゲナーゼ−2阻害剤の使用方法
Trummlitz et al. The pharmacology of new-generation nonsteroidal anti-inflammatory agents: selective COX-2 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080213

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081008